Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]

AIDS

Volumn 20, Issue 7, 2006, Pages 1083-1085

  Boyd, Mark A ^a   Burger, David M ^b   Phanuphak, Praphan ^c   Cooper, David A ^d  

^a FLINDERS UNIVERSITY   (Australia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; STREPTOMYCIN;

ADULT; BACTERIUM CULTURE; CASE REPORT; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; KIDNEY DYSFUNCTION; LETTER; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; OXAZINES; RITONAVIR; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 33646382853     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222090.52035.b2     Document Type: Letter

References (13)

1. World Health Organization. Fact Sheet 104: Tuberculosis. Geneva: World Health Organization, 2005. http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed July 18 2005.
2. Ackah AA, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995; 345:607-610.
3. World Health Organization. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization; 2004. http://www.who.int/3by5/publications/documents/arv_ guidelines/en/
4. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR 2004; 53:RR15.
5. Pozniak AL, Miller RF, Lipman M.C.I. for the BHIVA Guidelines Writing Committee. BHIVA Treatment Guidelines for TB/HIV Infection. http://www.bhiva.org
6. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. http://www.hivatis.org Accessed 20 September 2005.
7. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19:1481-1486.
8. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect in press.
9. Roche. Drug-induced hepatitis in healthy volunteers receiving riafmpicin 600 mg daily in combination with ritonavir 100 mg and saquinavir 1000 mg twice daily. Safety Information Letter. Basel, Switzerland: Roche; 7 February 2005.
10. Justesen US, Andersen AB, Klitgaard K, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampicin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Inf Dis 2004; 38:426-429.
11. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1 infected Thai patients. Antivir Ther 2005; 10:301-307.
12. Mootsikapun P, Chetchotisakd P, Anannutsiri S, Bunyapravij P. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily in naive HIV-1 infected patients with CD4 < 200/mm3: 96-week outcomes. Antivir Ther 2005; 10:911-916.
13. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, et al. Efficacy of a twice daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.